Ontario Public Drug Programs
Executive Officer Communications
| Date | Title |
|---|---|
| 2020 | |
| August 24 | Executive Officer Notice: Funding of Riximyo (rituximab) and Ruxience (rituximab) under the Ontario Drug Benefit Program |
| August 5 | Executive Officer Notice: Funding of Allerject® (Epinephrine Auto-Injector) through the Allergen Program |
| July 30 | Executive Officer Notice: Inspections Return to Work |
| June 12 | Executive Officer Notice: Removal of the 30-days' Supply Dispensing Limit Recommendation |
| May 21 | Notice from the Executive Officer: Funding of Teva UK-labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler as a Temporary Benefit on the Ontario Drug Benefit (ODB) Formulary. English | French |
| May 13 | Notice from the Executive Officer: Regulatory Amendments to Ontario Drug Benefit Program Co-payments |
| May 13 | Notice from the Executive Officer: Changes to the Trillium Drug Program in Response to COVID-19 |
| May 1 | Notice from the Executive Officer: Proposed Regulatory Amendments to Ontario Drug Benefit (ODB) Program Co-payments and Dispensing Fees English | French |
| April 23 | Notice from the Executive Officer: Brand Reference Price Regulations Amendment English | French |
| April 23 | Notice from the Executive Officer: Drug Submissions for Ontario Drug Benefit (ODB) Program during the COVID-19 Public Health Emergency English | French |
| April 15 | Executive Officer Notice: Updated Quarterly Report Back Form for the Ontario Naloxone Program for Pharmacies (ONPP) English | French – Questions and Answers for the Updated QRBF English | French – Quarterly Report Back Form English | French |
| April 15 | Notice: Ontario Drug Benefit Program and Exceptional Access Program Changes during the COVID-19 Public Health Emergency English | French |
| April 7 | Notice from the Executive Officer: Regulation Amendments to Private Label Products and Brand Reference Pricing Rules English | French |
| April 1 | Notice: Extending Submission Period for Electronic Drug Claim Reversals AND The Ontario Drug Programs Reference Manual, Revision #1 English | French – Frequently Asked Questions English | French |
| April 1 | Notice: Policy for Methadone Maintenance Treatment Reimbursement under the Ontario Drug Benefit Program English | French – Frequently Asked Questions for Pharmacists English | French |
| March 30 | Notice from the Executive Officer: Proposed amendments to the effective date of changes to allow Private Label Products to be funded under the Ontario Drug Benefit (ODB) Program and Designated as Interchangeable Products on the ODB Formulary English | French |
| March 30 | Notice from the Executive Officer: Proposed Regulatory Amendments on Rules for Determining Brand Reference Prices English | French |
| March 30 | Notice from the Executive Officer: Funding of Truxima (rituximab) under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| March 23 | Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation English | French |
| March 23 | Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation English | French |
| March 20 | Notice: Ontario Drug Benefit (ODB) Program Changes and Guidance for Dispensers during the COVID-19 Public Health Emergency English | French |
| March 2 | Notice: Reconciliation Adjustment Percentages for 2020/21 to Improve the Value of Pharmacy Payments English | French |
| 2019 | |
| December 23 | Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act to reduce Administrative Burden to Drug Manufacturers and Pharmacies English | French |
| December 23 | Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation Notice English | French |
| December 16 | Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act and Regulation 935 made under the Drug Interchangeability and Dispensing Fee Act to reduce restrictions on Private Label Products and Ordinary Commercial Term benefits English | French |
| December 16 | Notice: Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020 |
| December 16 | Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Improve the Value of Pharmacy Payments English | French – Frequently Asked Questions for Pharmacists English | French |
| October 28 | Notice: Proposal to Improve the Value of Pharmacy Payments English | French |
| October 28 | Notice from the Executive Officer: Proposal to Reduce Administrative Burden to Drug Manufacturers and Pharmacies English | French |
| October 18 | Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System English | French – Frequently Asked Questions English | French |
| October 1 | Notice from the Executive Officer: Updates to the Drug Evaluation Process for Biosimilar Products English | French |
| September 12 | Notice from the Executive Officer: Funding Flash Glucose Monitoring System Through the Ontario Drug Benefit Program English | French |
| July 31 | Notice from the Executive Officer: Updated Funding of Erelzi (etanercept) under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| July 24 | Notice from the Executive Officer Submission Requirements: Flash GlucoseMonitoring (FGM) English | French |
| July 4 | Notice from the Executive Officer: Updates to the Ontario Guidelines for Drug Submission and Evaluation English | French |
| June 4 | Notice from the Executive Officer: Change to the Health Network System Subscription Agreement for Pharmacy Operators English | French |
| April 26 | Notice from the Executive Officer: Proposals to Establish More Efficient Pharmacy Reimbursement Policies English | French |
| March 13 | Notice from the Executive Officer: Buprenorphine/Naloxone (Suboxone® and generics) Reimbursement Reminder under the Ontario Drug Benefit Program English | French |
| February 27 | Notice from the Executive Officer: Amendment to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to make changes to Ontario Drug Benefit Program coverage for children and youth aged 24 years and under (OHIP+) English | French – Frequently Asked Questions for Patients English | French – Frequently Asked Questions for Pharmacists English | French |
| February 13 | Notice from the Executive Officer: Extension of the Temporary Facilitated Access Mechanism (Rheumatology) until March 31, 2019) English | French |
| February 1 | Notice from the Executive Officer: Administrative Monetary Penalty Issued for Acceptance of Rebates |
| January 2 | Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to make changes to Ontario Drug Benefit Program coverage for children and youth aged 24 years and under (OHIP+) English | French |
| 2018 | |
| December 31 | Notice from the Executive Officer: Interim Extension of the Temporary Facilitated Access Mechanism (Rheumatology) English | French |
| December 4 | Notice from the Executive Officer: Completion of Strengthening Pharmacy Payment Management English | French |
| October 29 | Notice from the Executive Officer: Proposed Amendments to Regulations under the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act relating to Private Label Products English | French |
| October 4 | Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines and Claims Submission using the Health Network System English | French – Frequently Asked Questions English | French |
| September 25 | Notice from the Executive Officer: Update on Claims Submission for Valved Holding Chambers through the Ontario Drug Benefit Program English | French |
| September 20 | Notice from the Executive Officer: Funding of Renflexis (infliximab) under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| September 20 | Notice from the Executive Officer: Funding of Glatect (glatiramer acetate) under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| September 10 (Updated October 11) |
Notice from the Executive Officer: Availability and Funding of AUVI-Q® (Epinephrine Auto-Injectors) as a Result of the Shortage of EpiPen® Products. English | French |
| August 14 | Notice from the Executive Officer: Claim Submission/Reversal and Special Authorization (Allergen) forms English | French |
| July 30 | Notice from the Executive Officer: Update on OHIP+ English | French |
| May 4 | Notice from the Executive Officer: Refreshed ODB Report Card English | French |
| May 1 | Notice from the Executive Officer: Update Regarding Strengthening Pharmacy Payment Management English | French |
March 29 |
Notice from the Executive Officer: Changes in the Way Pharmacies Verify Eligibility for Individuals Receiving Social Assistance |
| March 21 (Updated April 27) |
* Please also refer to entry April 15 under 2020 for new information on the Ontario Naloxone Program for Pharmacies (ONPP) in regards to the Quarterly Report Back Form. Notice from the Executive Officer: Funding of Naloxone Nasal Spray through the ONPP and Updates to the Existing Program |
| March 8 | Notice from the Executive Officer: Funding of Naloxone Nasal Spray through the ONPP English | French – Frequently Asked Questions English | French |
| March 5 | Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs English | French |
| March 2 | Notice from the Executive Officer: Ontario Drug Benefit Act Regulatory Amendment to Support the Ontario Basic Income Pilot (OBIP) English | French – Frequently Asked Questions English | French |
| February 21 | Notice from the Executive Officer: Funding of Hepatitis B Drugs under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| February 8 | Notice from the Executive Officer: Addition of Nurse Practitioners to the Palliative Care Facilitated Access (PCFA) Mechanism English | French |
| January 24 | Notice from the Executive Officer: Edition 43 of the Ontario Drug Benefit Formulary English | French |
| January 16 | Notice from the Executive Officer: Ontario Drug Benefit Act Proposed Regulatory Amendments to Align Maximum Days’ Supply of Prescriptions Dispensed for Ontario Works Recipients 25 years of Age and Older English | French |
| January 10 | Notice from the Executive Officer: Ontario Drug Benefit Act Proposed Regulatory Amendment to Support the Ontario Basic Income Pilot (OBIP) English | French – Frequently Asked Questions English | French |
| 2017 | |
| December 22 | Notice from the Executive Officer: Drug Submission – Submission Requirements: Valved Holding Chambers (VHCs) English | French |
| December 21 | Notice from the Executive Officer: Funding Valved-Holding Chambers through the Ontario Drug Benefit Program English | French |
| December 14 | Notice from the Executive Officer: Funding of Erelzi (etanercept) under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| December 14 | Notice from the Executive Officer: Temporary Facilitated Access Mechanism (Rheumatology) for Ontario Drug Benefit Recipients aged 24 years and under English | French |
| December 1 | Notice from the Executive Officer: Removal of the Special Authorization (Allergen) Form for Pharmacy Dispensing of Epinephrine Auto-Injectors for Ontario Drug Benefit recipients English | French |
| November 17 | Addendum: Notice from the Executive Officer: Addition of Agriflu® to the Universal Influenza Immunization Program English | French |
| October 13 | Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines and Claims Submission using the Health Network System for the 2017/2018 Influenza Immunization Season English | French – Frequently Asked Questions English | French |
| September 21 | Notice from the Executive Officer: Notice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for the Fentanyl Transdermal Patch English | French – Frequently Asked Questions English | French |
| September 21 | Notice from the Executive Officer: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Support the Homes for Special Care Modernization Initiative English | French |
| September 1 | Notice from the Executive Officer: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Strengthen Pharmacy Payment Management English | French |
| September 1 | Notice from the Executive Officer: Amendment to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare English | French |
| August 23 | Notice from the Executive Officer: Notice from the Executive Officer: Thyroid (Desiccated Thyroid) Delisting English | French |
| August 3 | Notice from the Executive Officer: Funding of Mifepristone/Misoprostol (Mifegymiso)
(updated December 7, 2017) English | French – Frequently Asked Questions for Health Care Providers (updated December 7, 2017) English | French – Frequently Asked Questions for Patients (updated December 7, 2017) English | French |
| August 1 | Notice from the Executive Officer: Funding of filgrastim under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| July 21 | Notice from the Executive Officer: Funding of Brenzys (etanercept) under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| July 11 | Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare Program English | French |
| July 7 | Notice from the Executive Officer: Ontario Drug Benefit Act, Legislative amendments to recognize the role of Nurse Practitioners in requesting Exceptional Access Program products and prescribing Listed Substances (Bill 87)
English | French – Frequently Asked Questions for Health Care Providers English | French |
| June 29 | Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Strengthen Pharmacy Payment Management English | French |
| March 16 | Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs English | French |
| February 21 | Notice from the Executive Officer: Funding of Hepatitis C drug products under the Ontario Drug Benefit Program English | French – Frequently Asked Questions for Health Care Providers English | French – Frequently Asked Questions for Patients English | French |
| January 27 | Notice from the Executive Officer: Updated Reminder Regarding Delisting of High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program English | French |
| 2016 | |
| December 21 | Notice from the Executive Officer: Funding of Grastofil (filgrastim) under the Ontario Drug Benefit program English | French – Frequently Asked Questions English | French |
| December 1 | Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| November 30 | Notice from the Executive Officer: Update Regarding Palliative Care Access to High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program English | French |
| October 24 | Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines for 2016-2017 Season and Claims Submission using the Health Network System English | French – Frequently Asked Questions English | French |
| October 07 | Notice from the Executive Officer: Application of Generic Substitution to the Exceptional Access Program English | French – Frequently Asked Questions for Patients English | French – Frequently Asked Questions for Pharmacists English | French – Frequently Asked Questions for Physicians English | French |
| September 26 | Notice from the Executive Officer: Regulation amendments to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products English | French |
| September 16 | Notice from the Executive Officer: Regulation to support the Safeguarding our Communities Act, 2015 (Patch for Patch Return Program) English | French – Frequently Asked Questions for Prescribers and Pharmacists English | French – Frequently Asked Questions for Patients English | French |
| September 16 | Notice from the Executive Officer: Drug Submission – Ontario Guidelines for Drug Submission and Evaluation 2016 English | French |
| September 02 | Notice from the Executive Officer: Changes in the Way Social Assistance Clients Access Drug Coverage – Updated Drug Eligibility Card Pharmacy Information Sheet For Social Assistance Clients – Drug Eligibility Card Client Information Sheet |
| August 17 (Updated April 27) | * Please refer to entry March 21 under 2018 for current information on the Ontario Naloxone Program for Pharmacies (ONPP). The materials below are available below for reference purposes. Notice from the Executive Officer: Reminder - Ontario Naloxone Program for Pharmacies (ONPP) Notice from the Executive Officer: Ontario Naloxone Program for Pharmacies (ONPP) – Frequently Asked Questions for Pharmacists |
| August 15 | Notice from the Executive Officer: Reimbursement and Claims Submissions using the Health Network System relating to Drugs for Medical Assistance in Dying English | French – Frequently Asked Questions for Pharmacists English | French |
| July 20 | Notice from the Executive Officer: Changes to the Ontario Drug Benefit (ODB) Program Funding of Opioid Medications English | French – Frequently Asked Questions for Pharmacists English | French |
| July 4 | Notice from the Executive Officer: MedsCheck Program Enhancements English | French |
| June 10 | Notice from the Executive Officer: Health Network System (HNS) Changes to Support the Maximizing Quantity Dispensed for Chronic-Use Medications Initiative English | French – Frequently Asked Questions English | French |
| June 1 | Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products English | French |
| June 1 | Notice from the Executive Officer: Proposed Regulation under the Safeguarding our Communities Act (Patch for Patch Return Policy) English | French |
| April 15 | Notice from the Executive Officer: Regulation Amendments to Expand Access to the Seniors’ Co-Payment Program under the Ontario Drug Benefit (ODB) Program English | French |
| March 22 | Executive Officer Notice Drug Submission – Information Bulletin English | French |
| March 15 | Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs English | French |
| March 11 | Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| February 29 | Notice from the Executive Officer:Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act to update cost-sharing arrangements for non-low income seniors under the Ontario Drug Benefit (ODB) program English | French |
| 2015 | |
| November 23 | Notice from the Executive Officer: New Blood Glucose Test Strip Reimbursement Policy English | French |
| November 13 | Notice from the Executive Officer: Claims submission for prescriptions with drug costs over $10,000 English | French – Frequently Asked Questions English | French |
| October 13 | Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2015-2016 Season and Claims Submission using the Health Network System |
| September 18 | Notice from the Executive Officer: Regulation Amendments to Streamline Submission Requirements for Certain Generic Products seeking Interchangeability Designations on the Ontario Drug Benefit Formulary English | French |
| September 18 | Notice from the Executive Officer: Regulation Amendments to Support Sustainability and Access for the Ontario Public Drug Programs English | French |
| September 18 | Notice from the Executive Officer: Supporting Sustainability and Access for the Ontario Drug Benefit Program English | French – Questions & Answers for Pharmacists English | French – Questions & Answers for Physicians English | French – Questions & Answers for Patients English | French – Chronic-use Medications List by Generic Name English |
| July 23 | Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act English | French – Questions & Answers for Patients English | French |
| May 20 | Notice from the Executive Officer: Tiered Generic Pricing Framework English | French |
| March 10 | Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs English | French |
| 2014 | |
| November 5, 2014 | Notice from the Executive Officer: Proposed Regulation Amendments to Establish a Pricing Framework for Certain Generic Products on the Ontario Drug Benefit (ODB) Formulary English | French |
| October 10 | Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2014-2015 Season and Claims Submission using the Health Network System English | French – Frequently Asked Questions updated November 21, 2014 English | French |
| March 11 | Notice from the Executive Officer: Reminder of the Upcoming Changes for April 1, 2014 [PDF] |
| March 10 | Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs [PDF] |
| 2013 | |
| November 28 | Notice from the Executive Officer: Edition 42 of the Ontario Drug Benefit Formulary [PDF] |
| November 26 | Notice from the Executive Officer: Accuracy in Claims Submissions [PDF] |
| October 4 | Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2013-2014 Season and Claims Submission using the Health Network System english | french |
| September 17 | Blood Glucose Test Strip Reimbursement Update [PDF] |
| July 11 | Notice to Pharmacies - Contacting the ODB Help Desk [PDF] |
| July 8 | Notice from the Executive Officer: Blood Glucose Test Strip Reimbursement Policy [PDF] english | french |
| June 11 | Notice from the Executive Officer: Professional Allowances Reporting Template for Drug Manufacturers [Excel] |
| March 7 | Notice from the Executive Officer: Reminder of the Upcoming Changes for April 1, 2013 |
| March 4 | Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs |
| February 20 | Important Notice from the Executive Officer: Proper Submission of Prescriber Identification to the Health Network System (HNS) and Narcotics Monitoring System (NMS) [PDF] |
| February 13 | Notice from the Executive Officer: Professional Allowances Reporting Template for Drug Manufacturers [Excel] |
| February 4 | Notice from the Executive Officer: FINAL Reminder Regarding the Funding Status of Oxycodone Controlled Release Tablet – OxyNEO [PDF] |
| January 24 | Notice from the Executive Officer: New Regulatory Requirements for Long-Acting Oxycodone Drug Products [PDF] |
| January 15 | Notice from the Executive Officer: Assignment of ON Numbers to Health Network System/Ontario Drug Benefit Accounts |
| 2012 | |
| December 20 | Notice from the Executive Officer: Expanded Scope of Practice and Accuracy in Claims Submission [PDF] |
| December 12 | Delisting of Aliskiren (Rasilez®) from the ODB Formulary - Questions & Answers |
| November 28 | Important notice regarding the prescribing and dispensing of Oxycodone CR. english | french |
| November 23 | Proposed Regulation Amendments to Set Additional Conditions for Submission Requirements of Long-Acting Oxycodone Drug Products english | french |
| October 10 | Notice to Pharmacies – Contacting the Help Desk [PDF] |
| October 9 | Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine and Claims Submission using the Health Network System; 2012-2013 Influenza Season - Fact Sheet - Q & As |
| October 4 | Notice from the Executive Officer: Important Reminder Regarding the Funding Status of Oxycodone Controlled Release Tablet - OxyNEO [PDF] |
| September 27 | Notice from the Executive Officer: Changes to the Transition Fee Payments under the Ontario Drug Benefit (ODB) Program |
| September 24 | Important Notice from the Executive Officer: Proper Submissions to the Narcotics Monitoring System (NMS) [PDF] |
| August 20 | Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers [Excel] |
| August 15 | Proposed Regulation Amendment to Reduce the Transition Fee Payments under the Ontario Drug Benefit (ODB) Program |
| May 8 | Important Notice from the Executive Officer: Submission of Monitored Drug Information to the Narcotics Monitoring System |
| April 12 | Notice from the Executive officer. Re: Implementation of the Narcotics Monitoring System (NMS) english | french |
| March 16 | Notice from the Executive Officer. Re: Upcoming Changes for April 1, 2012 |
| February 27 | Notice from the Executive Officer. Re: Pharmaceutical Opinion Program |
| February 17 | Notice from the Executive Officer: RE: Important Notice Regarding Change in Funding Status of Oxycodone Controlled Release Tablet – (Discontinuation of OxyContin and Introduction of OxyNEO) english | french |
| February 6 | Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers |
| 2011 | |
| December 6 | Notice from the Executive officer. Re: Prescriber ID Requirements for Claims Submitted on the Health Network System (HNS) |
| November 30 | Notice from the Executive Officer. Re: Additional Clarification Regarding the Narcotics Legislation |
| October 27 | Notice from the Executive Officer. Re: Additional Questions on the Narcotics Legislation english | french |
| October 14 | Important Notice to Health Care Providers on the New Requirements under the Narcotics Safety and Awareness Act, 2010 |
| October 14 | Public Notice Regarding the Ministry of Health and Long-Term Care's ("ministry") Collection, Use and Disclosure of Information under the Narcotics Safety and Awareness Act, 2010 english | french |
| September 9 | Suspension of Ontario Drug Benefit (ODB) Billing Accounts |
| August 31 | Notice from the Executive Officer. Re: MedsCheck Program Standardization and system Requirements |
| August 31 | Notice from the Executive Officer. Re: Pharmaceutical Opinion Program |
| August 29 | Notice from the Executive Officer. Re: Pharmacy Smoking Cessation Program |
| August 22 | Notice from the Executive Officer. Re: Expanding Professional Pharmacy Services for September 1, 2011 |
| July 28 | Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers |
| June 10 | Notice from the Executive Officer. Re: Extension of Transition Fee Payments and Conditions for Payment of Dispensing Fees for Remote Dispensing Location under the Ontario Public Drug Programs |
| May 24 | Clarification to the Notice from the Executive Officer. Re: Lucentis – Change in Status to Limited Use (April 1, 2011) |
| April 7 | Notice from the Executive Officer. Re: New Regulation under the Optometry Act, 1991 |
| April 4 | Notice from the Executive Officer. Re: Request for Qualification (RFQ) for Acquirer Host Network Services |
| April 1 | Notice from the Executive Officer. Re: EAP criteria change for rosiglitazone (Avandia) |
| April 1 | Notice from the Executive Officer. Re: Lucentis - Change in Status to Limited Use |
| March 29 | Notice from the Executive Officer. Re: Implementation of the first stage of expanded services |
| March 23 | Notice from the Executive Officer. Re: Expanding Professional Pharmacy Services for April 1, 2011 |
| March 23 | Notice from the Executive Officer. Re: Increase in Dispensing Fees, Effective April 1, 2011 |
| March 18 | Notice from the Executive Officer. Re: New Regulation under the Drug and Pharmacies Regulation Act (DPRA) |
| February 28 | Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers |
| February 09 | Notice from the Executive Officer. Re: Narcotics Monitoring System Questions and Answers |
| 2010 | |
| December 6 | Notice from the Executive Officer. Re: Formulary Listing for Enalapril Maleate |
| October 19 | Q & As for Change in Listing Status for Gabapentin |
| September 30 | Notice from the Executive Officer. Re: Pharmacy ONE Mail System Registration - Reminder Notice |
| September 8 | Notice from the Executive Officer. RE: MedsCheck Program Expanded Services Launched September 13, 2010 |
| August 26 | Notice from the Executive Officer: Change in Status to Limited Use (Humira and Enbrel) & New Limited Use Listing (Stelara) - Q & As for Change in Listing Status for Humira, Enbrel, and Stelara |
| August 23 | Notice from the Executive Officer. RE: Expanding Professional Pharmacy Services Working Group |
| July 13 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| June 08 | Notice from Ontario Public Drug Programs Re: Clarification of Digoxin Listings |
| January 25 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| 2009 | |
| July 17 | Policy to Acquire Medications for Treatment of Tuberculosis - Dear Pharmacist Letter. Communiqué from the Public Health Division, MOHLTC |
| July 15 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| May 6 | Notice from the Executive Officer: Change of Funding Status Rosiglitazone (Avandia®) and Pioglitazone (Actos® and Generics) - Q&As for TZD Funding Status Change |
| May 6 | Notice from the Executive Officer: Expanded Limited Use Criteria for Clopidogrel (Plavix) - Q&As for Clopidogrel Expanded LU Criteria |
| March 3 | Notice from the Executive Officer - MedsCheck Adjustment Payment to Pharmacies Ending on April 1, 2009 |
| February 23 | Notice from the Executive Officer: Ongoing Transparency Initiative: Public Posting of Drug Submission Status - Updates |
| February 4 | Notice from the Executive Officer: Reminder – Professional Allowance Reporting: July 1, 2008 to December 31, 2008 |
| January 13 | Notice from the Executive Officer: Academic Detailing Program - Q&As for Academic Detailing Program |
| 2008 | |
| December 19 | Notice from the Executive Officer: Health Network System (HNS) Enhancements to Support the Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program |
| December 17 | Notice from the Executive Officer: Renewal of the Health Network System (HNS) Subscription Agreement |
| December 1 | Notice from the Executive Officer: Enhancements to Health Network System to Support the Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program |
| December 1 | Notice from the Executive Officer: Announcement of Changes to the Formulary respecting Enalapril Maleate |
| November 17 | Notice from the Executive Officer: Telephone Request Service for Exceptional Access Program - Q&As for External Stakeholders |
| October 29 | Executive Officer Notice: Completing the New Health Network System (HNS) Agreement |
| October 27 | Executive Officer Notice: Price Increase Requests |
| October 20 | Notice of Termination and Replacement of Agreement: Ontario Public Drug Programs Subscription Agreement |
| October 3 | Notice from the Executive Officer: Public Consultation to Review the definition of Professional Allowance and the Codes of Conduct |
| October 2 | Notice from the Executive Officer: Notice of Termination and Replacement of Agreement: Ontario Public Drug Programs Subscription Agreement |
| September 30 | Notice From Executive Officer: Implementation Plan To Review The Definition Of Professional Allowance And The Code Of Conduct |
| September 19 | Notice from the Executive Officer: Notice Of Cancellation Of Call For Application For Ranitidine Hydrochloride |
| August 26 | Notice from the Executive Officer: Drug Submissions Requirement - Revised Letter of Consent |
| August 22 | Notice from the Executive Officer Reminder - Professional Allowance Reporting |
| August 5 | Notice from the Executive Officer: Claims for ZANTAC® under the Ontario Drug Benefit Program |
| July 28 | Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program - Questions and Answers |
| July 18 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| July 16 | Notice from the Executive Officer: Competitive Agreements Q&As |
| July 8 | Notice from the Executive Officer: Ontario Public Drug Programs Competitive Agreement - Briefing for Stakeholders |
| June 4 | Notice from the Executive Officer: Manufacturer Review of Transparency Bulletin |
| May 29 | Notice from the Executive Officer: Pricing of Products Reimbursed Under the Exceptional Access Program (EAP) |
| May 16 | Notice from Executive Officer |
| May 16 | Notice from Executive Officer: Limited Use (LU) Process Changes |
| May 13 | Notice from Executive Officer: Ongoing Transparency Initiative - Public Posting of Drug Submission Status. |
| April 17 | Notice from the Executive Officer: Lucentis Questions and Answers |
| April 15 | Recruitment for Pharmacy Council Members, letter from the Executive Officer |
| March 6 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| January 30 | 2008 BBS Notice from the Executive Officer: MedsCheck, Adjustment Payment to Pharmacies - a Reminder |
| 2007 | |
| November 15 | Notice from the Executive Officer, BBS Introducing the "Follow-up" MedsCheck, effective November 30, 2007 |
| November 15 | Recruitment for Pharmacy Council Members, letter from the Executive Officer |
| November 13 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| October 19 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| October 1 | Notice to Manufacturers Submission Requirements for Generic Drug Products |
| October 4 |
(BBS Nº.7079) Notice from the Executive Officer: Lead Time Between the Formulary Update and Effective Date |
| September 14 | (BBS Nº.7071) Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| July | Letter to Pharmacists from the Executive Officer: MedsCheck Update |
| July 13 | Notice to Pharmacists: MedsCheck Update |
| May 29 | (BBS Nº.7029) MedsCheck Update |
| May 8 | (BBS Nº.7025) Notice to Pharmacists from Executive Officer: Follow up to April 5, 2007 Notice |
| April 1 | Letter to Pharmacists from the Executive Officer: MedsCheck |
| February 21 | (BBS Nº.7009) Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| 2006 | |
| December 18 | (BBS Nº.6086) Notice from the Executive Officer: Amending Regulations under ODBA and DIDFA |
| September 28 | Notice to Pharmacists: Regulation Changes made to the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA) |
| April 13 | (BBS Nº.6029) Notice to Pharmacists: Bill 102, Transparent Drug System for Patients Act |
Public Information
